Methotrexate with citrovorum factor rescue reduced chemotherapy toxicity in the management of gestational trophoblastic neoplasms
- 1 February 1980
- Vol. 45 (3) , 423-426
- https://doi.org/10.1002/1097-0142(19800201)45:3<423::aid-cncr2820450303>3.0.co;2-g
Abstract
The comparative systemic toxicity of methotrexate (MTX) with citrovorum factor rescue (CF), MTX alone and actinomycin-D (Act-D) in the treatment of gestational trophoblastic neoplasms (GTN) was evaluated in the present study. Treatment with MTX-CF was associated with only a 4% incidence (1 of 25 patients) of hepatic and/or hematologic toxicity and total absence of either a generalized rash or marked alopecia. In contrast, both MTX alone and Act-D were associated with a 48% incidence (12 of 25 patients) of hepatic and/or hematologic toxicity. Actinomycin-D also induced a generalized rash and marked alopecia in 24% (6 of 25 patients) and 52% (13 of 25 patients) of the patients respectively. We found that MTX-CF is the least toxic single agent chemotherapeutic regimen in the management of GTN.This publication has 6 references indexed in Scilit:
- Physiologic Jaundice of the NewbornObstetrics & Gynecology, 1978
- Actinomycin D as the primary agent for gestational trophoblastic diseaseCancer, 1975
- Gestational trophoblastic diseaseAmerican Journal of Obstetrics and Gynecology, 1971
- Primary chemotherapy for nonmetastatic gestational trophoblastic neoplasmsAmerican Journal of Obstetrics and Gynecology, 1967
- Sequential use of methotrexate and actinomycin D in the treatment of metastatic choriocarcinoma and related trophoblastic diseases in womenAmerican Journal of Obstetrics and Gynecology, 1965
- Five years' experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in womenAmerican Journal of Obstetrics and Gynecology, 1961